Biotechnology UltraSector ProFund

The Biotechnology UltraSector ProFund seeks daily investment results, before fees and expenses, that are 1.5x the return of the Dow Jones U.S. BiotechnologySM Index (the "Index") for a single day.

View Prospectus

Fund Snapshot

Investor Class Service Class
Ticker BIPIX BIPSX
CUSIP 743185480 743185472
Fund Number 043 073
Inception Date 6/19/2000
Fund Group Sector ProFunds - UltraSector

Fund Statistics

Limits On Exchanges None
Minimum Investment
Individual Investor $15,000
Financial Professionals $5,000

NAV as of 12/19/2014

Class NAV % Change $ Change
Investor $69.64 1.89% $1.29 NAV History
Service $58.41 1.88% $1.08 NAV History
BIPIX Current Quote and Chart

Returns (as of 9/30/2014)

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost.

For standardized returns year-to-date, and as of the most recent calendar quarter-end, and annualized month-end, see performance. Returns include the reinvestment of dividends and capital gains.

YTD (as of 12/19/2014) 59.78%
Average Annual One Year 52.68%
Average Annual Three Year 73.98%
Average Annual Five Year 39.15%
Average Annual Ten Year 21.35%
Average Annual Since Inception 7.61%
Cumulative Since Inception 185.22%
Gross Expense Ratio 2.00%
Net Expense Ratio * 1.78%

* Contractual waiver effective from December 1, 2014 through November 30, 2015. Without such a waiver of fees, the total returns would have been lower.

All data, unless otherwise noted, is as of 9/30/2014 and for Investor Class Shares only and is subject to change.

Index/Benchmark

Dow Jones U.S. Biotechnology Index

The Index (Bloomberg symbol: DJUSBT) measures the performance of the biotechnology sector of the U.S. equity market. Component companies engage in research and development of biological substances for drug discovery and diagnostic development. These companies derive most of their revenue from the sale or licensing of drugs and diagnostic tools. It is not possible to invest directly in an index.ex.

Total Index Companies 29
Average Index Market Capitalization 24.65 billion

Index as of 9/30/2014

Top 10 Index Companies Weight
Gilead Sciences Inc. 22.51%
Amgen Inc. 14.92%
AbbVie Inc. 12.86%
Biogen Idec Inc. 10.93%
Celgene Corp. 10.60%
Alexion Pharmaceuticals Inc. 4.59%
Vertex Pharmaceuticals Inc. 3.74%
Regeneron Pharmaceuticals Inc. 3.72%
Illumina Inc. 3.20%
BioMarin Pharmaceutical Inc. 1.48%